Exploring mutation specific beta blocker pharmacology of the pathogenic late sodium channel current from patient-specific pluripotent stem cell myocytes derived from long QT syndrome mutation carriers.

MLA

Comollo, Thomas W., et al. “Exploring Mutation Specific Beta Blocker Pharmacology of the Pathogenic Late Sodium Channel Current from Patient-Specific Pluripotent Stem Cell Myocytes Derived from Long QT Syndrome Mutation Carriers.” Channels (19336950), vol. 16, no. 1, Dec. 2022, pp. 173–84. EBSCOhost, https://doi.org/10.1080/19336950.2022.2106025.

APA

Comollo, T. W., Zou, X., Zhang, C., Kesters, D., Hof, T., Sampson, K. J., & Kass, R. S. (2022). Exploring mutation specific beta blocker pharmacology of the pathogenic late sodium channel current from patient-specific pluripotent stem cell myocytes derived from long QT syndrome mutation carriers. Channels (19336950), 16(1), 173–184. https://doi.org/10.1080/19336950.2022.2106025

Chicago

Comollo, Thomas W., Xinle Zou, Chuangeng Zhang, Divya Kesters, Thomas Hof, Kevin J. Sampson, and Robert S. Kass. 2022. “Exploring Mutation Specific Beta Blocker Pharmacology of the Pathogenic Late Sodium Channel Current from Patient-Specific Pluripotent Stem Cell Myocytes Derived from Long QT Syndrome Mutation Carriers.” Channels (19336950) 16 (1): 173–84. doi:10.1080/19336950.2022.2106025.